Measles, smallpox, and poliomyelitis
|
|
- Charity May
- 5 years ago
- Views:
Transcription
1 Considerations for Implementing a New Combination Vaccine into Managed Care Lawrence Mullany, MD, MBA Abstract Background: The control and elimination of several deadly childhood diseases are a result of extensive vaccination efforts made by pediatricians, family practitioners, public health providers, and health outreach systems. Managed care can assist this effort through facilitating the delivery of affordable quality healthcare to patients. Objective: To describe the considerations made by managed care when implementing a new vaccine into practice. Results: Managed care plans often assess the medical necessity, consumer acceptance, and pharmacoeconomic benefits of a vaccine when considering whether it can be implemented into practice. DTaP-HepB-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine [Combined]), a new combination vaccine, has demonstrated similar immunogenicity and safety when compared with separately administered component vaccines. Use of this combination vaccine will help to simplify the current immunization schedule, and therefore decrease the number of injections infants receive in the first year of life, favorably influencing consumer perception of this new vaccine. A reduction in the number of office visits as a result of fewer injections and improved vaccine compliance may result in a positive pharmacoeconomic impact on parents, physicians, and payers. Reduced administration fees, fewer needed syringes, and decreased risk of needlestick injury resulting from the use of combination vaccines all may have a positive impact on acceptance of these vaccines by managed care organizations. Conclusion: DTaP-HepB-IPV is expected to meet the tests of medical appropriateness, consumer acceptance, and pharmacoeconomic reasonableness, thereby fulfilling the value proposition of a new combination vaccine for managed healthcare plans. (Am J Manag Care. 2002;9:S23-S29) Measles, smallpox, and poliomyelitis are now known historically in our culture rather than by their demonstrated devastation. Parents are no longer familiar with the heartache that infections with Haemophilus influenzae type b, diphtheria, or tetanus can inflict when a child becomes ill with one of these deadly diseases. This is a testament to the efforts and effectiveness of pediatricians and family practitioners and their respective nursing staffs, as well as public health providers and health outreach systems, to vaccinate our children. Managed care strives to facilitate the delivery of affordable high quality healthcare and to surmount barriers or hurdles that limit or restrict immunization successes. With the availability of a new vaccine, an analysis of the risks, benefits, barriers, and advantages of implementing this vaccine in managed care will need to determine the value of the vaccine. Value in this context is regarded as a formula that includes medical necessity, indication, and patient benefit divided by cost, both financial and human. The cost component of the value equation refers to the pharmacoeconomics of ingredient costs, administration costs, and cost impact on the community. DTaP-HepB-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine Combined) (Pediarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) is a new combination vaccine composed of diphtheria-tetanusacellular pertussis (DTaP) vaccine, hepatitis B virus (HepB) vaccine, and inactivated VOL. 9, NO. 1, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S23
2 poliovirus (IPV) vaccine in 1 vaccine that may be administered to infants in 3 injections to complete the required primary series of immunizations. Managed care plans will need to assess the medical necessity, consumer acceptance, and pharmacoeconomic benefits of this vaccine when considering whether it can be implemented in the respective plan s pediatric population. Assessing the Medical Necessity of a New Vaccine Assessing the medical necessity of a vaccine requires evaluation of its effectiveness in terms of immunogenicity, ease and simplicity of administration, and physician acceptance. The risk of failure in terms of side effects, unanticipated impacts, and unsolicited adverse perceptions also needs to be weighed. Additionally, the opinions of respected authorities and regulatory bodies are both significant and critical to the decision process of whether a vaccine is a medical necessity. DTaP-HepB-IPV has been studied extensively both in the United States and in Europe, where it has been in use since Much of the assessment by managed care of the immunogenicity and reactogenicity of this vaccine can be based on these clinical studies, as follows. A study conducted by Schmitt and colleagues 1 demonstrated that a high degree of seroprotection is attained against diphtheria, tetanus, hepatitis B, and the 3 poliovirus strains when DTaP-HepB-IPV is administered separately but concomitantly with Haemophilus influenzae type b vaccine (Hib) at 2, 3, and 4 months of age. In addition, at least 97% of study participants had a vaccine response to pertussis ( 5 ELISA [enzyme-linked immunosorbent assay] units per ml), and all subjects who received DTaP-HepB-IPV and Hib separately had postvaccination Hib anti-polyribosylribitol phosphate antibody concentrations of 0.15 µg/ml or higher. Usonis and Bakasenas 7 also evaluated the reactogenicity and immunogenicity of DTaP-HepB-IPV concomitantly administered with 3 licensed Hib vaccines at 3, 4.5, and 6 months of age. This study also demonstrated that DTaP-HepB-IPV did not interfere with the immunogenicity of Hib vaccines when administered separately. Both studies found the separate administration of DTaP-HepB-IPV and Hib to be safe and well tolerated. 1,7 In a randomized study comparing DTaP- HepB-IPV coadministered with Hib vaccine, and diphtheria-tetanus-whole-cell pertussis (DTwP)-IPV/Hib vaccine coadministered with HepB at 6, 10, and 14 weeks of age, DTaP-HepB-IPV + Hib was found to be at least as immunogenic as DTwP-IPV/Hib + HepB. 2 All infants received HepB within 48 hours of birth. However, there was a notable difference in the anti-hepatitis B surface antigen response postdose 2 between the 2 groups (98.6% of infants in the DTaP-HepB- IPV + Hib group vs 88.7% of infants in the DTwP-IPV/Hib + HepB group). A lower incidence of adverse events occurred following the administration of DTaP-HepB-IPV + Hib compared with DTwP-IPV/Hib + HepB, most likely because of the lower reactogenicity of DTaP-based vaccines compared with DTwPbased vaccines. 8 In summary, DTaP-HepB- IPV + Hib was demonstrated to be safe and well tolerated and similar in immunogenicity to DTwP-IPV/Hib vaccine coadministered with HepB. Even though DTaP-HepB-IPV was compared with a combination vaccine containing DTwP, these data may still be examined by managed care plans when evaluating the effectiveness of DTaP-HepB-IPV. Safety and immunogenicity also were studied in a head-to-head trial comparing DTaP-HepB-IPV with separate administration of DTaP, HepB, and oral poliovirus vaccine (OPV) at 2, 4, and 6 months of age, 3 described in further detail by Partridge and Yeh 9 elsewhere in this supplement. In this study, DTaP-HepB-IPV also was compared with DTaP-HepB + IPV at 2, 4, and 6 months of age. All infants received separate administration of Hib at 2, 4, and 6 months of age. No vaccine-related serious adverse events were noted and there were no significant differences in minor local or systemic adverse events among any of the cohorts after any dose. Immune response rates were not different among the groups for diphtheria, tetanus, pertussis, hepatitis B, Hib, or polio types 1, 2, and 3. This study further supports the conclusion that the safety and immunogenicity of DTaP-HepB-IPV is equiv- S24 THE AMERICAN JOURNAL OF MANAGED CARE JANUARY 2003
3 Considerations for Implementing a New Combination Vaccine into Managed Care alent to standard individually administered vaccines. The safety of DTaP-HepB-IPV coadministered with Hib vaccine at a separate site also was compared with individually administered DTaP, Hib, and OPV in a study published by Zepp and colleagues. 4 In this study of 5472 infants, reactogenicity of DTaP-HepB-IPV administered concomitantly with 1 of 4 different Hib vaccines given at separate injection sites was similar to that occurring with commercially available individual vaccines in terms of defined end points of safety. The trial demonstrated that a complex strategy of simultaneous administration of up to 6 different antigens can be achieved without increased risk of clinically significant adverse events. Therefore, assuming acceptance by physicians and regulatory bodies, these studies demonstrate that DTaP-HepB-IPV meets the medical necessity criteria for implementing a new combination vaccine into managed care. Consumer Acceptance of a New Vaccine Currently, 7 vaccines that protect against 11 diseases are administered in 20 injections during the first 2 years of life in order to comply with the immunization schedule recommended by the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). 10 As a result, 5 injections may be administered at a single visit. Introduction of DTaP-HepB-IPV into the immunization schedule at 2, 4, and 6 months of age would simplify administration of these vaccines by decreasing the necessary injections to 15 in the first 2 years of life, assuming a HepB birth dose is administered. From a member or parent perspective, this reduction in the number of injections administered is a major benefit of using DTaP-HepB-IPV in clinical practice. Of note, managed care organizations need to be aware of the perceptions about vaccines that exist among contemporary families. In a recent telephone survey conducted by Gellin and colleagues, 11 23% of parents stated that infants receive more vaccines than are good for them and 25% of parents believed that too many immunizations can overwhelm an infant s immune system, causing the infant to be susceptible to other diseases (Table 1). In addition, there is a large volume of unsubstantiated information available to parents that perpetuates myths about vaccines, resulting in poor healthcare practices because of fear. Allegations abound of vaccines causing diabetes, autism, infections, and a host of unsolicited adverse events. 12 Many websites amplify these claims by relying heavily on emotion- Table 1. Parents Perceptions About Immunizations* % Agree % Disagree (% Strongly (% Strongly Perception Agree) Disagree) Children should only be immunized 39 (20) 55 (31) against serious diseases. Children get more immunizations than 23 (10) 68 (37) are good for them. Immunizations are always proven safe 71 (33) 19 (7) before they are approved for use. I am concerned that my child s immune 25 (9) 63 (33) system could be weakened by too many immunizations. I am more likely to trust immunizations that 88 (64) 8 (3) have been around for a while. Immunizations are one of the safest forms 78 (41) 10 (4) of medicine ever developed. Immunizations are getting better and safer 89 (60) 4 (2) all the time, as a result of medical research. Vaccines strengthen the immune system. 71 (41) 11 (5) I have access to all the information I need 92 (70) 7 (4) to make good decisions about immunizing my children. Parents should be allowed to send their child 14 (6) 79 (63) to school even if not immunized. I am opposed to immunization requirements because: They go against freedom of choice. 18 (10) 75 (52) Only I know what is best for my child. 18 (9) 75 (47) Immunization requirements protect my child 84 (54) 11 (5) from getting diseases from unimmunized children. *Response scale for these questions is: strongly agree, agree, neither agree nor disagree, disagree, and strongly disagree. Source: Reproduced with permission from Gellin BG. 11 VOL. 9, NO. 1, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S25
4 al appeal to convey their messages of distrust and vaccination avoidance. 13 However, good science and evidence-based reviews exist that disprove these allegations. The Institute of Medicine has published a report, Immunization Safety Review: Multiple Immunizations and Immune Dysfunction, 14 which concludes that such allegations are baseless. The availability of new vaccines will require practitioners to review the benefits of immunization with parents and describe the consequences of not being vaccinated. Although there has been a dramatic decline in many of the diseases children are vaccinated against, 300 children die annually from vaccine-preventable diseases. 15 Additionally, vaccine-preventable childhood diseases can cause other serious consequences, including deafness, decreased motor function, liver damage, and coma. 16 More important, some of these diseases continue to occur in our communities. In the United States, an analysis of data on notifiable diseases demonstrated that more than 7000 cases of pertussis and more than 1000 cases of invasive H influenzae occurred in Although extremely rare, diphtheria carries a 10% mortality rate and a 50% hospitalization rate. 18 Tetanus kills 30% of those affected. Five percent of children with mumps develop meningitis or encephalitis. From a household perspective, a child with chicken pox misses 8 to 9 days of school and the parent misses 1 to 2 days of work. 19 Therefore, the use of DTaP-HepB-IPV in a managed care organization, with an overall reduction in the number of inoculations needed, may provide practitioners with more time to address any issues that parents might have about vaccination. Pharmacoeconomic Assessment of a New Vaccine With reductions in the number of visits needed to achieve a similar immune status, saved days of employment missed by parents, and reduced copays for fewer vaccinerelated office visits, there are obvious direct and indirect pharmacoeconomic benefits of using a combination vaccine, such as DTaP- HepB-IPV, for the member. There are also benefits and costs that must be weighed for the managed care plan when implementing a new vaccine in practice. Physicians currently incur costs in nursing time associated with vaccine preparation, injection, and administrative recording. This time expands with infant crying and distress in the office. A time-motion study published in 2000 clearly demonstrated a savings in time with the use of a combination vaccine, which may result in better quality of care and savings of administrative dollars spent in the office. 20 The investigators were able to demonstrate a reduction of 2.4 minutes per shot in examination room settings and 1.7 minutes per shot in an immunization room setting when administering a combination vaccine (Table 2). This time savings may also assist in reducing the likelihood of a medication error within the process of medication administration and transcription. Although difficult to quantify, other impacts to managed care organizations include a reduction in office visits because of fewer injections. In addition, fewer syringes are needed and there is a decreased risk of needlestick injury by handling fewer syringes. This may help to defray the costs that are associated with following the Needlestick Safety and Prevention Act (H.R. 5178), which requires safety devices, employee training, and Sharps Injury Log maintenance. 21 The Occupational Safety and Health Administration estimates that the average expenses associated with needlestick injuries or other blood exposures range from $500 to $3000, with the majority falling between $500 and $1000. It was further noted that if the needlestick injury were to result in an actual infection such as hepatitis or human immunodeficiency virus, the cost could be hundreds of thousands of dollars or more. 22 This is consistent with the recommendations of the AAP Infection Control Guidelines to avoid these problems. 23 The actual incidence of needlestick injuries sustained annually is not clearly defined. In a US General Accounting Office estimate based on the CDC National Surveillance System for Health Care Workers, about percutaneous injuries occur annually in hospitals, with 60% from hollow-bore needlestick injuries. 24 Twenty-six percent of these hospital injuries were S26 THE AMERICAN JOURNAL OF MANAGED CARE JANUARY 2003
5 Considerations for Implementing a New Combination Vaccine into Managed Care Table 2. Time Required Based on Number of Injections in the Injection Room and Examination Room in a Managed Care Organization* Mean Time (Min) By No. of Injections Mean Change (Min) Per Time Element Site Extra Injection P Preparation Injection room Examination room Injection Injection room <.001 Examination room <.001 Paperwork/ Injection room administrative Examination room Other vaccine- Injection room related time Examination room NA NA Total nurse time Injection room <.001 Examination room Care center Injection room <.001 personnel time to Examination room process patient NA indicates not applicable. *Linear regression of time vs number of injections adjusted for age. Mean minutes per extra injection. P value for trend. Source: Reproduced with permission from Pellissier JM. 20 caused by sudden patient movement at the time of needle insertion, manipulation, or removal. However, these data did not include the ambulatory settings where 60% of all healthcare workers are employed. According to the International Health-care Worker Safety Center at the University of Virginia in Charlottesville, it has been estimated that there have been at least sharps and blood contacts annually during the past decade. 25 It is logical to postulate that a reduction in the number of injections required for vaccination would reduce the risk of needlestick injury and therefore reduce the costs associated with these events. As a result of improved vaccination rates with combination vaccines, managed care organizations can document these results as a performance measure, such as a Health Plan Employer Data and Information Set (HEDIS) score, to recruit new members. These performance measures also serve to meet consumer demands for meaningful information about a managed care plan, and act as a comparative basis for selecting a managed care plan. 26 An analysis of HEDIS 3.0 measures found that the administrative cost per measure to a managed care plan can range from $ to $ as a result of several tasks, including the cost of reviewing charts, linking different data sets, cleaning the data, doing the calculations, and writing the reports associated with a measure. 14 In terms of vaccinations, much of this cost is in the collection of the data, which can be complicated and thus increasingly expensive to obtain by manual chart reviews and variable compliance. A simplified immunization schedule with VOL. 9, NO. 1, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S27
6 Table 3. Cost Benefit for Immunization of Infants Months of Age Cost Benefit Cost Benefit Vaccine Direct ($) * Indirect ($) Total ($) DTP Polio MMR Hib 1.4 # HepB 0.5** Varicella DTP indicates diphtheria and tetanus toxoids and pertussis vaccine; HepB, hepatitis B virus vaccine; Hib, Haemophilus influenzae type b vaccine; MMR, measles-mumps-rubella. *Direct costs include medical care savings from vaccination (physician fees, hospitalization, and disease sequelae). Indirect costs calculated as total minus direct costs. Total costs include medical care and nonmedical costs (direct costs plus costs for parent s loss of work time or transportation to the physician s office). Data are from reference 29. Data are from reference 30. Data are from reference 31. #Data are from reference 32. **Data are from reference 33. Data are from reference 34. Source: Adapted with permission from Gershon AA. 28 improved compliance may reduce the costs of acquiring these data as currently performed, and may enhance the collection and assessment of the data by allowing for administrative collection with a single code. In addition, simplifying the process may reduce the gap in children who should have received their scheduled immunizations by age 2 but have not. As noted in HEDIS 2002 national data (based on 2001 results), this gap ranges from 17% to 23% for 4DTP, 3IPV, and 3HepB immunizations specifically, and from 17% to 45% for most recommended vaccinations (4DTP, 3IPV, 3HepB, 1MMR, 3Hib, and 1Varicella). 27 When determining the overall economic value of a vaccine, the indirect savings of administering the vaccine must be weighed against the direct costs of the vaccine. For example, as shown in Table 3, every dollar spent on Hib vaccine saves $1.40 in direct costs and $0.80 in indirect costs (ratio, 2.2:1). 28 Likewise, every dollar spent on HepB vaccine saves $0.50 in direct costs and $1.50 in indirect costs (ratio, 2.0:1), and every $1.00 spent on varicella vaccine saves $0.90 in direct costs and $4.50 in indirect costs (ratio, 5.4:1). When using DTaP- HepB-IPV to complete the primary immunization series, an extra HepB dose may be administered if a HepB birth dose was given as recommended by the ACIP, AAP, and AAFP. Each managed care plan will need to examine the cost benefits of administering DTaP-HepB-IPV in relation to the cost of an extra HepB dose. There is no doubt as to the return on health and/or the return on investment of vaccinating when both the direct and indirect costs of a vaccine are taken into consideration. Conclusion In summary, DTaP-HepB-IPV should meet a managed care organization s tests for medical appropriateness, consumer acceptance, and pharmacoeconomic reasonableness, thereby fulfilling the value proposition for the vaccine. The immunogenicity and safety of this vaccine have been demonstrated in several clinical studies. The need for fewer injections with use of DTaP-HepB-IPV is expected to be well received by parents and healthcare providers, and should result in decreased costs for the parent, healthcare provider, and payer. In addition, better compliance with needed vaccinations should occur. DTaP-HepB-IPV will be a welcome addition to the vaccine armamentarium for managed care organizations. REFERENCES 1. Schmitt HJ, Knuf M, Ortiz E, Sänger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virusinactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 2000;137: Gylca R, Gylca V, Benes O, et al. A new DTPa-HBV- IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine coadministered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine. 2001;19: Yeh SH, Ward JI, Partridge S, et al. Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B and polio combination vaccine in infants. Pediatr Infect Dis J. 2001;20: S28 THE AMERICAN JOURNAL OF MANAGED CARE JANUARY 2003
7 Considerations for Implementing a New Combination Vaccine into Managed Care 4. Zepp F, Schuind A, Meyer C, Sänger R, Kaufhold A, Willems P. Safety and reactogenicity of a novel DTPa- HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics. 2002;109. Available at: http// 5. Blatter MM, Resinger K, Bottenfield GW, et al. Evaluation of the reactogenicity and immunogenicity of a new combined DTPa-HBV-IPV vaccine co-administered with Hib vaccine at 2, 4 & 6 months of age [abstract]. Clin Infect Dis. 1999;29: Bogaerts H. The future of childhood immunizations: examining the European experience. Am J Manag Care. 2002;8:S526-S Usonis V, Bakasenas V. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussishepatitis B virus-inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines? Eur J Pediatr. 1999;158: Brown F, Greco D, Mastrantonio P, Salmaso S, Wassilak S. Pertussis vaccine trials. Session IV: vaccine efficacy. Dev Biol Stand. 1997;89: Partridge S, Yeh SH. Clinical evaluation of a DTaP- HepB-IPV combined vaccine. Am J Manag Care. 2002;8:S509-S Centers for Disease Control and Prevention. Recommended childhood immunization schedule: United States, MMWR Morb Mortal Wkly Rep. 2002;51: Gellin BG, Maibach EW, Marcuse EK, for the National Network for Immunization Information Steering Committee. Do parents understand immunizations? A national telephone survey. Pediatrics. 2000;106: Offit PA, Quarles J, Gerber MA, et al. Address-ing parents concerns: do multiple vaccines overwhelm or weaken the infant s immune system? Pediatrics. 2002;109: Wolfe RM, Sharp LK, Lipsky MS. Content and design attributes of antivaccination web sites. JAMA. 2002;287: Stratton K, Wilson CB, McCormick MC, eds. Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Washington, DC: National Academy Press; National Committee for Quality Assurance. The state of managed care quality, 2001: childhood immunization status. Available at: somc2001/child_imm/somc_2001_cis.html. Accessed August 5, National Immunization Program. Vaccine-preventable childhood diseases. Available at: gov/nip/diseases/child-vpd.htm. Accessed August 5, Eberhardt MS, Ingram DD, Makuc DM, et al. Urban and Rural Health Chartbook. Health, United States, Hyattsville, Md: National Center for Health Statistics; Marquette County Health Department. Childhood immunization facts. Available at: marquette.localhealth.net/arcniiweek.htm. Accessed August 7, American Academy of Pediatrics. Varicella: the chickenpox vaccine. Available at: medem.com/search/article_display.cfm?path=n:&mstr=/ ZZZU7QBMH4C.html&soc=AAP&srch_typ=NAV_ SERCH. Accessed August 7, Pellissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care. 2000;6: Environmental & Occupational Health & Safety Services. Safe medical devices. Available at: MedicalDevices. Accessed August 16, US Department of Labor Occupational Safety and Health Administration. Record summary of the request for information on occupational exposure to bloodborne pathogens due to percutaneous injury. Available at: Accessed August 16, American Academy of Pediatrics. AAP releases infection control guidelines for physicians offices. Available at: jun.inf.htm. Accessed August 12, US General Accounting Office. Occupational safety: selected costs and benefit implications of needlestick prevention devices for hospitals. Available at: Accessed August 16, Flaherty M. A hazard to your health? Available at: html. Accessed August 16, Kongstvedt PR, ed. Member services and consumer affairs. The Managed Health Care Handbook. 4th ed. New York, NY: Aspen Publishers, Inc; 2001:chap National Committee for Quality Assurance (NCQA). Quality Compass Washington DC: NCQA; Gershon AA, Gardner P, Peter G, Nichols K, Orenstein W. Guidelines from the Infectious Diseases Society of America: quality standards for immunization. Clin Infect Dis. 1997;25: Hatziandreu E, Palmer CS, Brown RE, Halpern MT. A cost benefit analysis of the diphtheria-tetanus-pertussis (DTP) vaccine. Arlington, Va: Batelle, Medical Technology, Assessment and Policy Research Program; Hatziandreu E, Palmer CS, Halpern MT, Brown RE. A cost benefit of the OPV vaccine. Arlington, Va: Batelle, Medical Technology, Assessment and Policy Research Program; Hatziandreu E, Brown RE, Halpern MT. A cost benefit analysis of measles-mumps-rubella (MMR) vaccine. Arlington, Va: Batelle, Medical Technology, Assessment and Policy Research Program; Hatziandreu EJ, Brown RE. A cost benefit analysis of the Haemophilus influenzae type b (Hib) vaccine. Arlington, Va: Batelle; Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold DH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA. 1995;274: Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271: VOL. 9, NO. 1, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S29
The number of vaccines recommended
Benefits of Combination Vaccines: Effective Vaccination on a Simplified Schedule Daisy Dodd, MD Abstract Background: The number of recommended immunizations during childhood has increased significantly
More informationWith the increasing number of recommended. Clinical Evaluation of a DTaP-HepB-IPV Combined Vaccine REPORTS
Clinical Evaluation of a DTaP-HepB-IPV Combined Vaccine Susan Partridge, BSN, MBA; and Sylvia H. Yeh, MD Abstract Objective: To provide an overview of prelicensure clinical data for a new pediatric vaccine
More informationImmunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)
Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Guideline developed by Shelly Baldwin, MD, in collaboration with the ANGELS Team. Last reviewed by Shelly Baldwin,
More informationImmunizations are among the most cost effective and widely used public health interventions.
Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean
More informationAchievements in Public Health, Impact of Vaccines Universal... Children -- United States,
1 of 6 2/10/2005 7:40 PM Weekly April 02, 1999 / 48(12);243-248 Achievements in Public Health, 1900-1999 Impact of Vaccines Universally Recommended for Children -- United States, 1990-1998 At the beginning
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationVaccine recommendations for children are becoming
Safety and Reactogenicity of a Novel DTPa-HBV-IPV Combined Vaccine Given Along With Commercial Hib Vaccines in Comparison With Separate Concomitant Administration of DTPa, Hib, and OPV Vaccines in Infants
More informationOVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE
OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9
More informationDeployment of Combination Vaccines and STI vaccines
Deployment of Combination Vaccines and STI vaccines Advancing Prevention Technologies for Sexual and Reproductive Health Symposium Berkeley, Ca March 24, 2009 Eileen Yamada, MD, MPH California Department
More informationThe University of Toledo Medical Center and its Medical Staff, Residents, Fellows, Salaried and Hourly employees
Name of Policy: Policy Number: Department: Approving Officer: Responsible Agent: Scope: Healthcare Worker Immunizations 3364-109-EH-603 Infection Prevention and Control Hospital Administration Medical
More informationCOMBINATION VACCINE - THE IMPORTANCE AND ROLE IN PUBLIC HEALTH SET UP
34 Buletin Kesihatan Masyarakat Isu Khas 2000 COMBINATION VACCINE - THE IMPORTANCE AND ROLE IN PUBLIC HEALTH SET UP Rahman. I.* ABSTRACT Infectious diseases are the world's leading cause of death. Vaccines
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationVaccine Safety Workshop
Vaccine Safety Workshop Dean A. Blumberg, MD, FAAP Disclosure speakers bureau: sanofi pasteur Discussion off label use of FDA approved vaccines Vaccine Safety: Outline DB MS DB vaccine-preventable diseases
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationHealthcare Personnel Immunization Recommendations
Healthcare Personnel Immunization Recommendations Kathleen Harriman, PhD, MPH, RN California Department of Public Health Immunization Branch Vaccine Preventable Disease Epidemiology Section kathleen.harriman@cdph.ca.gov
More informationGuidelines for Quality Standards for Immunization
IDSA GUIDELINES Guidelines for Quality Standards for Immunization Pierce Gardner, 1 Larry K. Pickering, 3 Walter A. Orenstein, 3 Anne A. Gershon, 2 and Kristin L. Nichol 4 1 Department of Medicine, State
More informationPertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months.
Program Management 61_5 The wp vaccines have a considerably lower price than ap vaccines and, where resources are limited and the vaccine is well accepted by the local population, wp vaccine remains the
More informationVACCINES TRIUMPHS AND TRIBULATIONS. William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine
VACCINES TRIUMPHS AND TRIBULATIONS William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine Never in the history of human progress has a better and cheaper
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Study vaccines Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChildhood Immunization Status
emeasure Title emeasure Identifier (Measure Authoring Tool) Childhood Immunization Status 117 emeasure Version number 5.1.000 NQF Number 0038 GUID b2802b7a-3580-4be8-9458- 921aea62b78c Measurement Period
More informationCommunicable Disease & Immunization
Communicable Disease & Immunization Ingham County Health Surveillance Book 2016 Communicable Disease & Immunization - 1 Communicable Disease & Immunization T he control of communicable disease and immunization,
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationPublic Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.
ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.
More informationDuring the past decade, additions to the recommended childhood immunization
Immunogenicity and Safety of a Combination Diphtheria, Tetanus Toxoid, Acellular Pertussis, Hepatitis B, and Inactivated Poliovirus Vaccine Coadministered with a 7-Valent Pneumococcal Conjugate Vaccine
More informationThe Use of Combination Vaccines in the United States
The Use of Combination Vaccines in the United States John W Ward, MD Senior Scientist, CDC Director, Program for Viral Hepatitis Elimination Task Force for Global Health Revised 2018 Combination Vaccine
More informationUtah s Immunization Rule Individual Vaccine Requirements
Utah s Immunization Rule Individual Vaccine Requirements Which vaccines are required for school entry in Utah? Grades K-6: 5 doses DTaP (4 doses if the 4 th dose was given after the 4 th birthday) 4 doses
More informationRECOMMENDED IMMUNIZATIONS
Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years
More information8: Applicability
Chapter 14 New Jersey State Sanitary Code Immunization of Pupils in Schools (New Jersey Administrative Code Citation 8:57-4.1 to 8:57-4.20) (Readopted with amendments September 20, 2003. Effective Date:
More informationECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES
ECONOMICS OF THE VACCINE MARKET: SIZE, GROWTH AND REVENUES 1 Relationship between research funding and burden of disease Source: Global Forum for Health Research Monitoring Financial Flows for Health Research
More informationSchool Nurse Regional Update School Year Immunizations COLORADO IMMUNIZATION BRANCH
School Nurse Regional Update 2017-18 School Year Immunizations COLORADO IMMUNIZATION BRANCH Talking Points Child Care Immunizations K through 12 th Grade Immunizations Official Medical and Non-Medical
More informationEarly Learning Centre Immunisation Policy Legislation ACT Public Health Regulations (2000)
Early Learning Centre Immunisation Policy Legislation ACT Public Health Regulations (2000) National Quality Standard / Education and Care Services National Regulations Standard 2.1 Each child s health
More informationOUR BEST SHOT: The Truth About Vaccines for You and Your Loved Ones VACCINES. Produced in partnership with
OUR BEST SHOT: The Truth About Vaccines for You and Your Loved Ones VACCINES Produced in partnership with OUR BEST SHOT: The Truth About Vaccines for You and Your Loved Ones Vaccines are one of the greatest
More informationTITLE 64 INTERPRETIVE RULE DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR PUBLIC HEALTH
TITLE 64 INTERPRETIVE RULE DEPARTMENT OF HEALTH AND HUMAN RESOURCES BUREAU FOR PUBLIC HEALTH SERIES 95 IMMUNIZATION REQUIRMENTS AND RECOMMENDATIONS FOR NEW SCHOOL ENTERERS 64-95-1. General. 1.1. Scope.
More informationA Publication for Local Health Departments & TVFC Providers serving Health Service Regions 2 & 3. Texas Immunization Rates most Improved in Nation
THE SHARPSHOOTER April 2009 A Publication for Local Health Departments & TVFC Providers serving Health Service Regions 2 & 3 Texas Immunization Rates most Improved in Nation During the 43 rd National Immunization
More informationPractical Applications of Immunology. Chapter 18
Practical Applications of Immunology Chapter 18 I. Vaccines A. Definition A suspension of organisms or fractions of organisms that is used to induce immunity (immunologic memory). The mechanism of memory
More informationChildhood Immunization
Childhood Immunization Version 2; last updated Oct 20, 2015 Prepared by Michael V. Maciosek, PhD 1 Amy B. LaFrance, MPH 1 1 HealthPartners Institute 8170 33 rd Avenue South PO Box 1524, MS 23301A Minneapolis
More informationDisclosures. Vaccines Save Lives, So Why the Pushback and What to do About It? Learning Objectives. ACIP History and Charge
Disclosures s Save Lives, So Why the Pushback and What to do About It? David W. Kimberlin, M.D. University of Alabama at Birmingham I have no actual or potential conflict of interest in relation to this
More informationRoutine Office Visits
Routine Office Visits Routine office visits are scheduled in advance. Since the office computer allows us to book appointments months in advance, you will often be able to make your next appointment as
More informationVACCINATION. DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
VACCINATION DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M. IMMUNIZATION Immunization is defined as the procedure by which the body is prepared to fight against a specific disease. It is used to induce the
More informationQuest for Quality: Immunizations
Quest for Quality: Immunizations DANE COUNTY IMMUNIZATION COALITION MEMBERSHIP MEETING November 13, 2012 Elaine Rosenblatt MSN, FNP-BC Director, Quality and Care Management UW Medical Foundation/ Unity
More informationVaccines and other immunological antimicrobial therapy 1
Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationIOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule
IOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule Bruce Gellin, MD, MPH Director, National Vaccine Program Office Deputy Assistant Secretary
More informationNew Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines
New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)
More informationHelp protect your child. At-a-glance guide to childhood vaccines.
Help protect your child. At-a-glance guide to childhood vaccines. 40976_CDCupdate.indd 1 Why vaccines matter. Thanks to widespread vaccination programs, several diseases that can infect our children have
More informationWalter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate Director, Emory Vaccine Center
Could Vaccines be a Possible Model For Pediatric Drug Development? June 13, 2006 Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics Director, Emory Vaccine Policy and Development Associate
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationHelp protect your child. At-a-glance guide to childhood vaccines.
Help protect your child. At-a-glance guide to childhood vaccines. Why vaccines matter. Thanks to widespread vaccination programs, several diseases that can infect our children have been eliminated. But
More informationHelp protect your child. At-a-glance guide to childhood vaccines.
Help protect your child. At-a-glance guide to childhood vaccines. Why vaccines matter. Thanks to widespread vaccination programs, several diseases that can infect our children have been eliminated. But
More informationTHIS FORM IS FOR MEDICAL STUDENTS ONLY IMMUNIZATION RECORD
Student Health Requirements Student health forms (physical exam and immunization records) are due in the Office of Clinical Education by March 1st for those students admitted on or before December 31st,
More informationWHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases
National Center for Immunization & Respiratory Diseases WHY WE RE HERE Melinda Wharton, MD, MPH Director, Immunization Services Division AIM Leadership Conference February 8, 2017 Vaccines save lives.
More information46825 (260) $UPONT
Be wise. Immunize. Keeping track of the shots your children receive can be confusing. This is an important responsibility that is shared by you and your immunization providers. This booklet contains the
More informationAppendix An Assessment Tool to Determine the Validity of Vaccine Doses
Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for
More information'Contagious Comments' Department of Epidemiology
'Contagious Comments' Department of Epidemiology Vaccine-Preventable Diseases in Colorado s Children, 27 Sean O Leary MD, Elaine Lowery JD MSPH, Carl Armon MSPH, James Todd MD Vaccines have been highly
More informationVaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines
Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines
More informationAPEC Guidelines Immunizations
Pregnancy provides an excellent opportunity to enhance a woman s protection against disease and to provide protection to the neonate during the first 3 to 6 months of life. Women of childbearing age should
More informationVaccinations and Vaccine- Preventable Diseases. Paul R. Cieslak, MD Public Health Division February 28, 2019
Vaccinations and Vaccine- Preventable Diseases Paul R. Cieslak, MD Public Health Division February 28, 2019 Vaccines prevent a lot of disease. Disease 20 th Century Annual Morbidity* Reported Cases, 2016
More informationVaccine-Preventable Diseases in Colorado s Children 2009 Sean O Leary MD, Carl Armon PhD, Joni Reynolds, RNC, MSN, James Todd MD
State of the Health of Colorado s Children Vaccine-Preventable Diseases in Colorado s Children 29 Sean O Leary MD, Carl Armon PhD, Joni Reynolds, RNC, MSN, James Todd MD Vaccines have been highly effective
More informationSummary of Methods. Figure 1: Vaccines have been very effective in reducing most vaccine-preventable diseases in Colorado.
The Children s Hospital March 2004 Marsha Anderson, MD James Todd, MD Vaccine-preventable Diseases in Colorado s Children, 2002 For More Information: The Children s Hospital Public Affairs Department 303-861-8555
More informationPediatric Quality Measure Information Sheet 2017
Prevention and Screening Adolescent Preventive Care Measures (APC) The percentage of adolescents 12-17 years of age who had at least one outpatient visit with a PCP or OB/ GYN practitioner during the measurement
More informationGENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES
GENERAL IMMUNIZATION GUIDE FOR CHILDCARE PROVIDERS August 2018 **CHILD VACCINES** DIPHTHERIA, TETANUS, PERTUSSIS VACCINES DTaP: Diphtheria, Tetanus, acellular Pertussis Vaccine Infanrix Licensed in 1997
More informationSetting The study setting was primary care. The economic analysis was conducted in the USA.
Predicted effects of a new combination vaccine on childhood immunization coverage rates and vaccination activities Meyerhoff A S, Greenberg D P, Jacobs R J Record Status This is a critical abstract of
More informationCurrent Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan
Research and Reviews Current Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan JMAJ 53(2): 106 110, 2010 Hajime KAMIYA,* 1 Tomoe SHIMADA,* 2 Nobuhiko OKABE* 3 Abstract
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationCHILDHOOD IMMUNIZATIONS
CHILDHOOD IMMUNIZATIONS APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What immunizations should be administered? NCQA ACCEPTED CODES DOCUMENTATION
More informationCALIFORNIA CODE OF REGULATIONS TITLE 17, DIVISION 1, CHAPTER 4
CALIFORNIA CODE OF REGULATIONS TITLE 17, DIVISION 1, CHAPTER 4 Article 1. Definitions 6000. Admission. Admission means a pupil's first entry in a given public or private elementary or secondary school,
More informationWho makes these rules? 04/19/2013. Guidelines for vaccine schedules Vaccine information materials Worksheets for assessing immunization i records
2013 Childcare Provider Immunization Training Please sign in, take a packet and pretest Objectives Know immunization exemptions allowed in Nevada Identify immunizations required and recommended for childcare
More informationCyprus Experience. Dr. Elena Papamichael Ministry of Health
Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey
More informationCopyright regulations Warning
COMMONWEALTH OF AUSTRALIA Copyright regulations 1969 Warning This material has been reproduced and communicated to you by or on behalf of the University of Melbourne pursuant to part VB of the Copyright
More informationJournal Club 3/4/2011
Journal Club 3/4/2011 Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants JAMA. 2011 Feb 9;305(6):576-84. Jones et al Dept of Pediatrics, Imperial College,
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChanges for the School Year. The addition of NINTH grade to the requirement for four (4) doses of diphtheria, tetanus, and pertussis.
February 19, 2013 Dear Immunization Provider: In accordance with South Carolina Code of Laws, Section 44-29-180, and State Regulation 61-8, the 2013-2014 "Required Standards of Immunization for School
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationPreventive care guidelines for children and adults.
Preventive care guidelines for children and adults. Keeping a focus on regular preventive care can help you and your family stay healthy. Preventive care can help you avoid potentially serious health conditions
More informationWashtenaw County Community Mental Health HEALTH CARE PERSONNEL (HCP) VACCINES (RECOMMENDED EMPLOYEE IMMUNIZATIONS)
Washtenaw County Community Mental Health HEALTH CARE PERSONNEL (HCP) VACCINES (RECOMMENDED EMPLOYEE IMMUNIZATIONS) PURPOSE To reduce the risk of exposure of Washtenaw County Community Mental Health (CMH)
More informationNote from the National Guideline Clearinghouse (NGC): The guideline recommendations are presented in the form of tables with footnotes (see below).
Brief Summary GUIDELINE TITLE Recommended immunization schedules for persons aged 0 through 18 years: United States, 2009. BIBLIOGRAPHIC SOURCE(S) American Academy of Pediatrics Committee on Infectious
More informationHOW DO VACCINES WORK?
Official Topic from UpToDate, the clinical decision support resource accessed by 700,000+ clinicians worldwide. Available via the web and mobile devices, subscribe to UpToDate at www.uptodate.com/store.
More informationCPT 2016 Code Changes
CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer
More informationUnit 2: Lesson 3 Development of Vaccines
Unit 2, Lesson 3: Teacher s Edition 1 Unit 2: Lesson 3 Development of Vaccines Lesson Questions: o What is the purpose of a vaccine? o What are the different ways in which vaccines are made? o How do vaccines
More informationHepatitis B Birth Dose: A Self-Study Module for the Maternal and Child Health Nurse
Hepatitis B Birth Dose: A Self-Study Module for the Maternal and Child Health Nurse With a special feature on frequently asked questions about vaccines Purpose: The purpose of this activity is to expand
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationimmunisation in New Zealand
This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were
More informationPreventive care is important at every age. Making good health choices now can boost your health and well-being for a lifetime.
Adult Recommendations Preventive care is important at every age. Making good health choices now can boost your health and well-being for a lifetime. Asthma and COPD Well-Child Visits Children s Immunization
More informationIMMUNIZATION COMPLETION RATES
Biennial Report of IMMUNIZATION COMPLETION RATES BY 24 MONTHS OF AGE To the Governor, the President of the Senate and the Speaker of the House of Representatives March 2004 Anthony D. Rodgers Director
More informationImmunization Policy. "UIC/COD-sponsored graduate education program" is one for which UIC/COD maintains academic responsibility.
I. PURPOSE Immunization Policy TITLE: CLINICAL HEALTHCARE PROVIDERS - IMMUNIZATIONS AND HEALTH REQUIREMENTS To prevent or reduce the risk of transmission of vaccine-preventable and other communicable diseases
More informationPATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures
PATH Quick Reference Guide: Coding for Pediatric Health HEDIS Measures This guide is designed to be a quick reference tool to help with medical coding of select Healthcare Effectiveness Data and Information
More informationWelcome to the California Immunization Coalition Education Hour
Welcome to the California Immunization Coalition Education Hour 1 . New School Rules: What Providers and Parents Need to Know Webinar Objectives Understand the impact of Senate Bill 277 on medical practices
More informationRecommended Health Screenings
Recommended Health Screenings UnitedHealthcare appreciates the preventive care you deliver to our members. Please use the below health screening chart to schedule screenings based on the member s age and
More informationJ Formos Med Assoc 2011;110(6): Contents lists available at ScienceDirect. Journal of the Formosan Medical Association
Volume 110 Number 6 June 2011 Perinatal factors and psychiatric disorders Intracellular defense against HIV Hypolipidemia and anti-hcv therapy Drug resistance of tuberculosis in diabetes patients Formosan
More informationDecision-making by the Advisory Committee on Immunization Practices
Decision-making by the Advisory Committee on Immunization Practices Melinda Wharton, MD, MPH Deputy Director, National Center for Immunization & Respiratory Diseases Institute of Medicine 9 February 2012
More informationBenefit Interpretation
Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents
More informationVaccines: Heroes or Villains?
Vaccines: Heroes or Villains? (Hint: It s the first one) James W. Jarvis, MD, FAAFP Senior Vice President/Senior Physician Executive Northern Light Eastern Maine Medical Center 1 Vaccinations: A brief
More informationUse of Infanrix -IPV+Hib in the infant primary immunisation schedule
Use of Infanrix -IPV+Hib in the infant primary immunisation schedule An update for registered healthcare practitioners July 2014 Quality Education for a Healthier Scotland 1 Acknowledgments Many thanks
More informationExpanded Programme on Immunization (EPI):
Expanded Programme on Immunization (EPI): Introduction Four to five million annual deaths could be prevented by 2015 through sustained and appropriate immunization efforts, backed by financial support.
More informationMinistry of Health, Screening and Vaccination Requirements from 1 January 2019
Ministry of Health, Screening and Vaccination Requirements from 1 January 2019 Mumps, Measles and Rubella (MMR) All students should be immune or vaccinated. Documented proof of vaccination (2-dose series);
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationAcknowledgements. Introduction. Structure of the video
Educators Guide Acknowledgements The Ministry of Health would like to thank Blue Bicycle Flicks. Thanks also to the staff and students from Evans Bay Intermediate School who contributed to the shooting
More information